本帖最后由 老马 于 2012-1-13 21:20 编辑 / ?- q; Z6 C/ [6 H9 Z6 ]
; G4 g; [4 \! B8 b- H; S
爱必妥和阿瓦斯丁的比较+ r3 t/ v% u; B: C, L" J
7 ?1 W6 m5 y2 U7 r m4 b. X$ }http://cancergrace.org/lung/2008/08/30/bms099-os-neg/3 N; u* G8 g" m' @* S* x" ]6 P( a4 a
1 m, [' Y, g' E) U+ v$ ]
% C* r$ o7 e1 }- u0 d. K! e G
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ e, j, a4 m6 |: y$ h0 I7 ^
==================================================
( I* f! ?) i6 }Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
' f& M/ r5 Z% e' IPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.7 N3 y0 i) f+ H( ~5 M) z8 N3 ]
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
d3 y5 E( W# _( p# A2 d
|